loader
Page is loading...
Print Logo Logo
Kelly Brilleaux
OVERVIEW

Kelly E. Brilleaux

Partner

Kelly Brilleaux is an experienced product liability litigator, focusing her practice on both individual and complex mass tort litigation. Kelly has extensive experience in pharmaceutical and medical device multidistrict litigation (MDL) in both national counsel and liaison counsel roles across multiple MDLs. She has represented clients in consumer mass tort litigation, along with environmental and toxic tort litigation.

OVERVIEW

Kelly Brilleaux is an experienced product liability litigator, focusing her practice on both individual and complex mass tort litigation. Kelly has extensive experience in pharmaceutical and medical device multidistrict litigation (MDL) in both national counsel and liaison counsel roles across multiple MDLs. She has represented clients in consumer mass tort litigation, along with environmental and toxic tort litigation.

Kelly has significant experience in conducting expert discovery and related motion practice, including identifying and communicating with medical, scientific, and other technical defense expert witnesses to assist with preparation of expert reports and deposition testimony. Kelly is actively involved in virtually all stages of litigation, including trial team preparation, handling discovery disputes, negotiating settlements and preparing Rule 702 Motions to Exclude plaintiffs' technical expert witnesses.

Committed to excellence both in and out of the courtroom, Kelly’s approach is characterized by her dedication to detail, collaborative spirit, and relentless advocacy for her clients. She applies her communication and problem-solving skills to provide creative, effective, and efficient solutions for clients.

In addition to her practice, Kelly excels in client development and organizational leadership. She has successfully led initiatives to strengthen client relationships and foster diversity within the legal field. Kelly is highly regarded for her ability to manage large-scale trial preparations, coordinate with multidisciplinary teams, and mentor emerging legal talent.

Honors

Co-recipient, FDCC Diversity Award, 2024

Louisiana Super Lawyers, Rising Star, 2015-2023

Best Lawyers in America, 2021-2023

Professional and Community Involvement

Member, Trial Attorneys of America

Chair, Federation of Defense & Corporate Counsel (FDCC) Products Liability Substantive Law Section

Vice chair, FDCC Drug and Medical Device Substantive Law Section

Chair, FDCC State and International Representative Program

Member, FDCC Diversity Committee

Executive Council Member, Association of Defense Trial Attorneys (ADTA) Class of 2026

Sponsorship Chair, Defense Research Institute Drug and Medical Device Committee

Member, Defense Research Institute Drug and Medical Device Committee Seminar Planning Committee

Member, Federal Bar Association

Past chair, Association of Defense Trial Attorneys (ADTA) We Prefer to Refer Committee

Past member, Louisiana Bar Association

Past member and secretary, New Orleans Bar Foundation

Past chair, New Orleans Bar Foundation Young Lawyer’s Section

EXPERIENCE
Presentations
  • FDCC 2024 Winter Meeting, “Institutional to Innovative: New Arguments in Products Liability,” Feb. 25, 2024
  • New Orleans Bar Association Procrastinator's Program, “Lessons Learned: A Young Lawyer’s Perspective on Professionalism in Drug and Device Litigation,” Dec. 11, 2018
  • New Orleans Bar Association Delegation to Panama, “Fundamentals of Comparative Legal Ethics: The United States, Latin America, and Beyond,” Oct. 7, 2017
  • New Orleans Bar Association Procrastinator's Program, “Legal Ramifications of Pokémon Go!,” Dec. 14, 2016
Publications
  • DRI For the Defense, “Tort Taxes: The Impact on the US Citizen and the Drug and Device Lawyer,” October 2023
  • DRI: The Voice, “For the Public Good: Conquering Apprehension Created by Pro Bono Fallacies,” July 29, 2020
  • DRI Rx For the Defense, “The Right, the Test, and the Vote: Heeding the Heeding Presumption in Pharmaceutical and Medical Device Failure to Warn Litigation,” July 9, 2020
  • DRI Rx For the Defense, “Direct-to-Consumer Advertising: Current and Future Landscape,” Jan. 22, 2019
  • Best Lawyers Business Edition, “Product Liability in 3D,” Summer 2016
  • DRI RX For the Defense, “Has the FDA Determined That Direct-To-Consumer Advertising Provides Too Much Information?” Jan. 30, 2015
  • DRI For the Defense, “Reevaluating the 401/403 Balance in 21st Century Mass Torts, February 2014
  • DRI For the Defense, “The Collateral Source Rule and Gratuitous Payments or Services,” November 2012
INSIGHTS AND EVENTS
Trending Connect
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to use cookies.